ClinicalTrials.gg

Program

janagliflozin

Also written as “ganagliflozin”, “Janagliflozin plus metformin” and “Janagliflozin 25mg”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by 2 companies.

Furthest: phase 4, since Jul 23, 20254 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huadong Medicine22 open or runningphase 4since Jul 23, 2025Jul 23, 2025Dec 31, 2027phase 4 · NCT07244003
Sihuan Pharmaceutical Holdings Group20 open or runningphase 3since Jan 17, 2019Jan 17, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 17, 2019First study: phase 3 study in Diabetes Mellitus, Type 2New to Sihuan Pharmaceutical Holdings GroupSihuan Pharmaceutical Holdings Group · NCT03811548 · 442 enrolled · China
  2. Feb 20, 2019Phase 3 study in Diabetes Mellitus, Type 2Sihuan Pharmaceutical Holdings Group · NCT03851432 · 390 enrolled · China
  3. Jul 23, 2025Huadong Medicine's first study: phase 4 study in Diabetes Mellitus, Type 2New to Huadong MedicineHuadong Medicine · NCT07116928 · 1,244 planned · China
  4. Nov 16, 2025Phase 4 study in Diabetes Mellitus, Type 2Huadong Medicine · NCT07244003 · 430 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 4 study in Diabetes Mellitus, Type 2Huadong Medicine · NCT07244003
  2. Oct 30, 2031Primary completion: phase 4 study in Diabetes Mellitus, Type 2Huadong Medicine · NCT07116928

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07244003Diabetes Mellitus, Type 2 · China4RecruitingHuadong MedicineDec 31, 2027430
NCT07116928Diabetes Mellitus, Type 2 · China4Not yet recruitingHuadong MedicineOct 30, 20311,244
NCT03851432Diabetes Mellitus, Type 2 · China3UNKNOWNSihuan Pharmaceutical Holdings GroupApr 30, 2020390
NCT03811548Diabetes Mellitus, Type 2 · China3UNKNOWNSihuan Pharmaceutical Holdings GroupJun 24, 2020442

How it is read

Names in the registry

  • “ganagliflozin”, 2 entries
  • “Janagliflozin plus metformin”, 2 entries
  • “Janagliflozin 25mg”, 1 entry
  • “Janagliflozin 50mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.